info@seagull-health.com
SeagullHealth
search
Pacritinib(Vonjo)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Vonjo(Pacritinib) Instructions:Uses,Dosage, Side Effects
VONJO (pacritinib) is a prescription kinase inhibitor supplied as 100 mg capsules. It is characterized by its distinct mechanism of action, which selectively targets key kinases like JAK2, FLT3, and IRAK1 without inhibiting JAK1. This profile positions it as a specialized therapeutic option for managing myelofibrosis in adults presenting with significant thrombocytopenia, a condition where treatment choices are often limited.
VONJO is indicated for the treatment of adult patients with intermediate or high-risk primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera or post-essential thrombocythemia) who have a baseline platelet count below 50 × 10⁹/L. This approval was granted under an accelerated pathway based on the endpoint of spleen volume reduction.
The standard dosage is 200 mg (two 100 mg capsules) taken orally twice daily.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
